From the 2020 Joint Annual Meeting (June 29, 2020)
Presented by Carlo Ledesma, MS, SH(ASCP)QLS, MT(ASCPi)
Clonal hematopoiesis (CH) is most commonly used to refer to a group of related myeloid cells with an acquired gene mutation. CH is seen in some of myelodysplastic syndromes and leukemias, but it may also be found in some individuals who have no detectable malignancy; in such cases it may be referred to as clonal hematopoiesis of indeterminate potential (CHIP).
At the conclusion of this presentation, participants will be able to:
- Identify the different methodologies in detecting clonality
- Summarize CHIP-associated mutations
- Discuss the different classification of clonal hematopoiesis
This recorded presentation is P.A.C.E. ® accredited. The instruction level for this activity is Intermediate. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of Hematology will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.
LEVEL OF INSTRUCTION
This intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.